(NYSE: JNJ) Johnson & Johnson's forecast annual revenue growth rate of 6.66% is forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.43%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.48%.
Johnson & Johnson's revenue in 2020 is $80,856,000,000.On average, 5 Wall Street analysts forecast JNJ's revenue for 2021 to be $233,129,146,805,520, with the lowest JNJ revenue forecast at $230,566,882,999,650, and the highest JNJ revenue forecast at $235,645,599,482,925. On average, 5 Wall Street analysts forecast JNJ's revenue for 2022 to be $244,917,608,649,186, with the lowest JNJ revenue forecast at $241,037,621,959,725, and the highest JNJ revenue forecast at $248,156,776,636,125.
In 2023, JNJ is forecast to generate $259,097,474,586,488 in revenue, with the lowest revenue forecast at $255,902,543,299,575 and the highest revenue forecast at $262,292,405,873,400.